Lymphopenia Should Never be Overlooked

INTRODUCTION

Lymphocytes include T lymphocytes, B lymphocytes, and natural killer (NK) cells, which are essential parts of the immune system. They mediate antibody production and direct cell-mediated killing of virus-infected and tumor cells. In healthy adults, the total white blood cell count ranges from 4,000 to 11,000/mL, with lymphocytes comprising about 30–40% of that population. Of all the lymphocytes, roughly 75% are T lymphocytes, 20% are B lymphocytes, and 5% are NK cells. Approximately 65% of circulating T cells are CD4+ helper T cells. Typical ranges for circulating T cells in adults are CD4+ T cells: 300–1,300/mL and CD8+ T cells: ~600/mL. Lymphocytopenia is defined as a total lymphocyte count below 1,000/mL. Organ transplant recipients are in need of lifelong immunosuppressive therapy to prevent rejection and preserve allograft function. Optimal immunosuppression and close surveillance are essential for successful outcomes, but these therapies can reduce absolute lymphocyte count (ALC) and impair lymphocyte function.

KEY IMMUNOSUPPRESSIVE AGENTS AND THEIR EFFECTS ON LYMPHOCYTES INCLUDE

• Tacrolimus (a calcineurin inhibitor): It inhibits T-cell proliferation and preferentially suppresses Th1 more than Th2 responses, reduces T cell–mediated cytotoxicity, and indirectly diminishes B-cell growth and antibody production by lowering T cell–derived growth factors

• Everolimus: Inhibits antigen and cytokine (interleukin [IL]-2, IL-15)-driven activation and proliferation of T and B lymphocytes

• Mycophenolic acid: Suppresses proliferation and maturation of T and B lymphocytes, suppresses cellular and humoral responses

• Corticosteroids: Produce differential effects on lymphocyte subsets involved in immunoglobulin synthesis diminishing B-cell responsiveness and removing suppressor T-cell activity and leaving helper T-cell function intact.

CLINICAL FEATURES/PRESENTATION/DIAGNOSIS

Per se, lymphopenia does not cause any symptoms. It is always a chance finding on laboratory tests done during febrile illness and other probable systemic infections such as protracted diarrhea, generalized malaise, loss of appetite, weight loss, and chronically protracted inflammatory states (mostly seen in immunocompromised patients, Organ Transplant Recipients on lifelong immunosuppressants) such as

• Frequent respiratory infections, such as influenza or pneumonia

• Unusual infections caused by atypical microbes, viruses, fungi, or parasites that rarely cause problems for people who have healthy immune system

• Long-lasting infections such as tuberculosis

• Enlarged lymph nodes

• Skin conditions and abnormalities such as sudden alopecia, eczema, pyoderma, pale skin, small bruises, and oral thrush

• History of exposure to human immunodeficiency virus (HIV) infection such as intravenous drug use, sexual partners, exposure to infectious blood or bodily fluids at work, or blood transfusions

• Cancer treatments such as radiation, chemotherapy, or immunotherapies

• Any hematological disorder or immune disorder.

LABORATORY TESTS

• A complete blood count with differential leukocyte count evaluates the numbers of lymphocytes, as well as red blood cells, platelets, and other types of leukocytes

• Flow cytometry can be used to identify and measure the levels of the different types of lymphocytes such as T cells, B cells, and NK cells

• Immunoglobulin level measures the levels of immunoglobulins, which are produced by B lymphocytes

• Other tests to be done to rule out different diseases that cause lymphopenia, such as HIV, COVID-19, or other viruses, tuberculosis, or other blood or immune conditions

• Bone marrow aspiration and fine needle aspiration cytology of lymph nodes aid in cytological examination.

CLINICAL IMPLICATIONS

Lymphopenia contributes to immunosuppression by reducing CD4⁺ and CD8⁺ T-cell function, impairing antigen presentation, and causing cytokine dysregulation. This immune dysfunction increases susceptibility to nosocomial, viral, and opportunistic infections, which can progress to multiorgan complications such as acute kidney injury (AKI), septic or cardiogenic shock, myocardial infarction, arrhythmias, and mortality.^[1] Clinical evidence links lymphopenia, especially persistent CD4+ T-cell lymphopenia, to adverse outcomes across several settings. In a retrospective study of patients with microscopic polyangiitis receiving immunosuppression, data showed that lymphopenia was associated with subsequent severe infections, which required hospitalizations.^[2] In another study among patients with anti-neutrophil cytoplasmic antibody-associated vasculitis on immunosuppression, CD4+ lymphocyte count was a better predictor of overall infection risk than total lymphocyte count.^[3] In renal transplant patients, prolonged CD4+ T-cell depletion increased post-transplant morbidity and mortality.^[4] Lymphopenia increases susceptibility to severe viral infections (e.g., cytomegalovirus [CMV], human polyomavirus) and has been identified as an independent risk factor for pneumocystis pneumonia.^[5] In heart transplant recipients, low ALCs predicted early CMV infection.^[6]

Lymphopenia in cardiac surgical patients in the perioperative period and intensive care unit (ICU) always signals a higher risk of infection, organ dysfunction, and mortality. In patients undergoing surgery for acute aortic dissection, pre-operative lymphopenia has been shown to correlate with higher rates of post-operative complications, including AKI, infections, arrhythmias, myocardial infarction, and increased in-hospital mortality.^[7] Among heart transplant recipients, severe lymphopenia (ALC < 500/mL) during the early post-transplant period up to 30 days predicted early CMV infection as well as other serious nosocomial and opportunistic infections. This condition is independently associated with increased mortality over the subsequent 11 months.^[8] Very low early ALC in heart transplant patients necessitates intensified CMV viral load surveillance and aggressive anti-CMV prophylaxis.^[5] In addition, careful balancing of maintenance immunosuppression against the risk of rejection is required, with early consideration of dose reduction or regimen modification in cases of severe, persistent lymphopenia accompanied by infection.

In critical care settings, patients with lymphopenia are particularly vulnerable to severe ICU-acquired infections and persistent lymphopenia independently predicts higher 28-day mortality.^[9] For patients with persistent severe lymphopenia (ALC < 500/mL), it is recommended to intensify infection prevention strategies and implement early diagnostic measures for ventilator-associated pneumonia, central line-associated bloodstream infections, Clostridioides difficile infection, and other opportunistic infections.^[10]

CONCLUSION

Persistent lymphopenia is associated with higher rates of opportunistic infections, malignancies, increased mortality, and graft rejection. Sustained infection surveillance is essential for patients who develop lymphopenia while on immunosuppressive therapy. Further research is needed to define how T-cell subtyping and detailed immune monitoring can guide individualized immunosuppression and enable earlier detection and prevention of infections.